GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback